Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 2,971,000 shares, a growth of 13.3% from the May 31st total of 2,622,200 shares. Based on an average daily volume of 7,800 shares, the short-interest ratio is presently 380.9 days.

Innovent Biologics Stock Performance

OTCMKTS:IVBXF opened at $4.71 on Wednesday. The stock’s fifty day moving average is $4.86 and its two-hundred day moving average is $4.86. Innovent Biologics has a 52 week low of $3.55 and a 52 week high of $6.41.

About Innovent Biologics

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.